News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Akebia Therapeutics, Inc. (AKBA), Trading M&A For An IPO—Becoming A Huge Contender In Anemia Drug Race


6/9/2014 6:54:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Akebia Therapeutics and its investors had hit a crossroads familiar to many startup biotechs last year. Its lead drug, AKB-6548, a pill for the anemia people get when their kidneys are failing, had just produced good enough data to move it into a Phase 2b study. If that went well too, the company would need to do a pricey late-stage trial if the drug were to have a chance to make it to market. So more money was needed—a lot of it. Meanwhile, rival drugs, some further along in development, were advancing.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy


comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES